[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-364073-105":59,"doc-detail-364073-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","methodology-of-analysis-of-cognitive-impairment-in-longitudinal-randomized-clinical-trials-in-oncology-scoping-review","Methodology of analysis of cognitive impairment in longitudinal randomized clinical trials in oncology - scoping review","","Cancer-related cognitive impairment (CRCI) is a frequent consequence of cancer treatments, and longitudinal randomized controlled trials are needed to evaluate cognitive outcomes over time. However, methodological heterogeneity reduces comparability across studies. This scoping review systematically examines how cognition is assessed in longitudinal oncology RCTs, with attention to study design, statistical approaches, cognitive measures, and adherence to reporting guidelines.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/methodology-of-analysis-of-cognitive-impairment-in-longitudinal-randomized-clinical-trials-in-oncology-scoping-review/364073/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/methodology-of-analysis-of-cognitive-impairment-in-longitudinal-randomized-clinical-trials-in-oncology-scoping-review/364073.png","ImageObject",300,407,{"name":92,"@type":93},"hdkawk","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",15,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main objective of the scoping review?","Question",{"text":113,"@type":114},"To examine methodological practices for assessing cognitive outcomes in cancer-related cognitive impairment research, specifically within longitudinal oncology randomized controlled trials.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were the studies selected and what data were extracted?",{"text":118,"@type":114},"The review included longitudinal RCTs published between 2010 and 2026 in adult cancer patients, extracting sample size, assessment tools, and statistical methods used to analyze cognition.",{"name":120,"@type":111,"acceptedAnswer":121},"What key findings emerged about cognition assessment methods?",{"text":122,"@type":114},"Across 113 included studies, cognition endpoints and objective measures were common, but recommended international cognitive tests were underused and scoring heterogeneity was observed; adherence to reporting guidelines was limited, especially for missing data and analysis sample details.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},364073,1790197717,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":31,"preview_page_count":19,"preview_urls":145},3985747859855,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Supportive Care in Cancer (2026) 34:905  \n[https://doi.org/10.1007/s00520-026-1](https://doi.org/10.1007/s00520-026-1)1059-1  \nMethodology of analysis of cognitive impairment in longitudinal randomized clinical trials in oncology: a scoping review  \nFrançois Christy1,3 · Florence Joly1,2,3,4 · Marie Lange1,2,3 · Mylène Duivon1,2 · Justine Lequesne1,2,3  \nReceived: 10 March 2026 / Accepted: 27 July 2026 © The Author(s) 2026  \nAbstract  \nPurpose Cancer-related cognitive impairment (CRCI) is a common consequence of cancer treatments. Longitudinal randomized controlled trials (RCTs) are essential to evaluate cognitive outcomes over time, but methodological heterogeneity limits comparability. Accordingly, we systematically review cognition assessment in longitudinal oncology RCTs, focusing on study design, statistical methods, cognitive measures, and adherence to reporting guidelines.  \nMethods We reviewed longitudinal RCTs published between 2010–2026 assessing cognition in adult cancer patients. Extracted data included sample size, assessment tools, statistical methods. Methodological quality of reporting was assessed using a subset of the CONSORT 2025 checklist.  \nResults One-hundred and thirteen studies were included. Trials involved 21% central nervous system (CNS) tumours and 50% of trials focused on breast cancer. Overall, 73% assessed the effects of interventions on cognition, and 27% the impact of cancer or its treatments. Cognition was a primary endpoint in 66% of trials. Objective measures predominated, but International Cognition and Cancer Task Force-recommended tests were underused, and heterogeneity in scoring was observed. The overall RCT median sample size was 81 participants (range: 8–867) . Statistical methods varied and were not mutually exclusive: 11% used descriptive analyses only; 24% baseline-adjusted/paired regression; 57% repeated measures; 11% other models. Adherence to reporting guidelines was limited, particularly for missing data (26%) and analysis sample (22%) . Conclusion Longitudinal cognitive assessments in oncology RCTs displayed heterogeneity in endpoints, tools, and statistical methods. Small sample sizes limit robustness of results. Future trials should prioritize primary cognitive objective, ensure adequate sample sizes, employ standardized cognitive assessments and appropriate statistical methods to enhance reproducibility and interpretability.  \nKeywords Cognition · Oncology · Longitudinal studies · Guidelines · Chemotherapy-related cognitive impairment · Randomized controlled trial  \n* François Christy [f.christy@baclesse.unicancer.fr](f.christy@baclesse.unicancer.fr)  \n1 ANTICIPE U1086 INSERM-UCN, Equipe Labellisée Ligue Contre Le Cancer, Centre François Baclesse, Normandie Université UNICAEN, 14000 Caen, France  \n2 Services Unit PLATON, Cancer and Cognition Platform, University of Caen Normandy, Caen, France  \n3 Clinical Research Department, UNICANCER, Centre François Baclesse, 14000 Caen, France  \n4 Medical Oncology Department, Centre François Baclesse Caen, Caen, France  \nIntroduction  \nCancer incidence has increased worldwide due to aging, lifestyle changes and environmental factors. Early detection and improvements in treatment and patient monitoring have extended survival[1], yet many survivors face persistent challenges, including cognitive impairments[2–4] .  \nCancer-related cognitive impairment (CRCI), initially referred to as “chemo-brain,” is increasingly recognized as a significant consequence of cancer and its treatments, occurring not only in central nervous system (CNS) cancers, but also in non-CNS cancers[5 , 6] . CRCI can result from multiple interacting factors, including the direct effects of the disease, systemic therapies such as chemotherapy, endocrine or targeted therapies, surgical interventions, and  \npsychological factors[7–9] . CRCI affects various cognitive domains, including memory, attention, executive functions, and processing speed[10] . Cognitive symptoms va","cbCaiuLnzAT0moCs","https://ap.wps.com/l/cbCaiuLnzAT0moCs","pdf",2471284,"English","# Abstract\n# Introduction\n# Methods","[{\"question\":\"What is the main objective of the scoping review?\",\"answer\":\"To examine methodological practices for assessing cognitive outcomes in cancer-related cognitive impairment research, specifically within longitudinal oncology randomized controlled trials.\"},{\"question\":\"How were the studies selected and what data were extracted?\",\"answer\":\"The review included longitudinal RCTs published between 2010 and 2026 in adult cancer patients, extracting sample size, assessment tools, and statistical methods used to analyze cognition.\"},{\"question\":\"What key findings emerged about cognition assessment methods?\",\"answer\":\"Across 113 included studies, cognition endpoints and objective measures were common, but recommended international cognitive tests were underused and scoring heterogeneity was observed; adherence to reporting guidelines was limited, especially for missing data and analysis sample details.\"}]","Methodology of analysis of cognitive impairment in longitudinal randomized clinical trials in oncology - scoping review | PDF",1790155528,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a737203b66800bb2b21f4601e1066db9.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/183c6c999034d4d693ab8cb747e368bb.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0e61d09a9a8945f0a30fb40cc83ae326.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6cc94f53a0244310264296e5fe45e49a.webp",980,1301]